BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced a definitive agreement to acquire the global development and commercialization rights to Benuvia Therapeutics Inc.’s (“Benuvia”) synthetic cannabidiol oral solution (“RAD011”). The Company plans to initiate a pivotal Phase 2/3 study for patients with Prader-Willi syndrome (“PWS”) in the second half of 2021 pending regulatory discussion with the U.S. Food and Drug Administration (“FDA”).

View original post here:
Radius Health, Inc. Announces Acquisition of Orphan Disease Program

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *